http://www.fpnotebook.com/
Vitiligo
Aka: Vitiligo
- Pathophysiology
- Immune-mediated Melanocyte destruction
- Family History present in up to 30% of patients
- Occurs equally in men and women
- Epidemiology
- Affects 1% of the population
- Onset peaks between age 10-30 years (50% occur by age 20 years)
- Types
- Generalized Vitiligo (>10% of body surface area involved)
- Acral or Acrofacial Vitiligo (tip-lip pattern: face and distal extremities)
- Localized Vitiligo (stable involvement of a small body area)
- Segmental Vitiligo (single dermatome or extremity involved - seen more in children)
- Signs
- Sharply demarcated, white, unpigmented Macules 0.5 to 5 cm in size
- Distribution
- Face and neck
- Dorsal hands
- Genitalia
- Intertriginous folds and axillae
- Periocular, periumbilical, and perianal areas
- Management: General
- Sun protection is critical (clothing, Sunscreen)
- Management: Cosmetic
- Concealers (e.g. Dermablend)
- Topical Corticosteroids
- Class II-III Topical Corticosteroids (e.g. Betamethasone 0.05% ointment or cream)
- Phototherapy with Psoralens (PUVA)
- Depigmentation (indicated for >40% of BSA involvement)
- Permanent depigmentation with Monobenzone 20% cream
- Requires 6-18 months for full treatment
- Surgical grafting
- May be used for localized, stable lesions
- References
- Njoo (1999) Arch Dermatol 135(12):1514-21
- Plensdorf (2009) Am Fam Physician 79(2): 109-16